Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from Reviva Pharmaceuticals Holdings ( (RVPH) ) is now available.
On February 13, 2025, Reviva Pharmaceuticals Holdings’ Compensation Committee approved several compensation arrangements for its executives, with retroactive base salary increases effective from January 1, 2025. Additionally, the committee set new bonus targets for 2025 and approved significant stock option grants, reflecting confidence in the leadership team and aligning their interests with shareholders.
More about Reviva Pharmaceuticals Holdings
Reviva Pharmaceuticals Holdings, Inc. operates in the pharmaceutical industry, focusing on developing and commercializing therapies for unmet medical needs, particularly in the central nervous system and respiratory sectors.
YTD Price Performance: -10.45%
Average Trading Volume: 3,018,118
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $83.84M
For an in-depth examination of RVPH stock, go to TipRanks’ Stock Analysis page.